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Abstract
Objectives: To investigate the natural history of chronic pancreatitis (CP), patients in the North 
American Pancreatitis Study2 (NAPS2, adults) and INternational Study group of Pediatric 
Pancreatitis: In search for a cuRE (INSPPIRE, pediatric) were compared.
Methods: Demographics, risk factors, disease duration, management and outcomes of 224 
children and 1,063 adults were compared using appropriate statistical tests for categorical and 
continuous variables.
Results: Alcohol was a risk in 53% of adults and 1% of children (p<0.0001); tobacco in 50% of 
adults and 7% of children (p<0.0001). Obstructive factors were more common in children (29% vs 
19% in adults, p=0.001). Genetic risk factors were found more often in children. Exocrine 
pancreatic insufficiency was similar (children 26% vs adult 33%, p=0.107). Diabetes was more 
common in adults than children (36% vs 4% respectively, p<0.0001). Median emergency room 
visits, hospitalizations, and missed days of work/school were similar across the cohorts. As a 
secondary analysis, NAPS2 subjects with childhood onset (NAPS2-CO) were compared to 
INSPPIRE subjects. These two cohorts were more similar than the total INSPPIRE and NAPS2 
cohorts, including for genetic risk factors. The only risk factor significantly more common in the 
NAPS2-CO cohort compared with the INSPPIRE cohort was alcohol (9% NAPS2-CO vs 1% 
INSPPIRE cohorts, p=0.011).
Conclusions: Despite disparity in age of onset, children and adults with CP exhibit similarity in 
demographics, CP treatment, and pain. Differences between groups in radiographic findings and 
diabetes prevalence may be related to differences in risk factors associated with disease and length 
of time of CP.
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Introduction
Chronic pancreatitis (CP) is a fibro-inflammatory disease of the pancreatic parenchyma with 
variable and complex etiologies, features and severity 1. Episodic and chronic pain, which is 
frequently intractable, leads to loss of work and school time 2–5, and increased utilization of 
healthcare resulting in high medical costs 6, 7. CP is most commonly described in adults as 
associated with excessive use of alcohol and tobacco 8. CP is increasingly recognized as a 
disease of children, 2, 9–12, although the prevalence of disease is lower than in adults 13. This 
may represent a true rise in prevalence in children or improved ascertainment.
Two large, multicenter studies have described the characteristics of individuals with CP: The 
North American Pancreatitis Study 2 (NAPS2, adults) 14–16 and the International Study 
Group of Pediatric Pancreatitis: In Search for a Cure (INSPPIRE, children) 2, 17, 18. Both 
groups recruited individuals from secondary and tertiary referral centers. Each examined 
demographic and risk factors for CP, and disease-related outcomes in a cross-sectional 
manner.
The separate analyses of pediatric and adult CP cohorts hamper investigation of the full 
clinical course of CP. Genetic risk factors are reported to be more common in children than 
in adults with CP 2. However, this difference may represent true differences in the genesis of 
CP in children compared with adults or may represent differences in clinical practice; that is, 
providers treating adults are less likely to order genetic testing. Adults and children may 
have differences in the progression of CP, or it may be that reports in adults and children 
represent an ongoing disease examined at different stages. Recent guideline publications by 
both adult and pediatric pancreas experts highlight the need to understand the full spectrum 
of disease 19, 20.
This study compares the NAPS2 and INSPPIRE CP cohorts, examining demographics, risk 
factors, disease duration, management and outcomes. Our goals are to better understand the 
natural history of CP and to initiate a dialog on protocols for care across age groups to 
improve outcomes across the age spectrum.
Methods
Study design and participants
INSPPIRE is a cross-sectional, multi-national study from 19 institutions, collecting 
demographic and clinical data by means of two sets of questionnaires: one completed by the 
patient or parent and the other completed by the physician on children who fulfilled the 
criteria for CP and were <19 years old at the time of enrollment 18. Diagnosis of CP required 
at least 1 of the following: (1) abdominal pain plus imaging suggestive of changes associated 
with chronic pancreatic; (2) exocrine pancreatic insufficiency and imaging findings 
suggestive of chronic pancreatic damage; or (3) endocrine pancreatic insufficiency and 
imaging findings suggestive of chronic pancreatic damage 21. Data for this analysis was 
entered into the Research Electronic Data Capture (REDCap, hosted at University of Iowa) 
database between August 22, 2012 to March 20, 2017 and represents baseline information 
from the cohort. All centers had institutional review board approval or the equivalent for 
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their country. All centers obtained written informed consent and assent, when required, from 
parents and children. Some of the pediatric patients included in this study have been 
previously reported 2, 17, 22–24.
The NAPS2 is a series of three sequential cross-sectional studies (original NAPS2 study 14, 
NAPS2 continuation and validation and NAPS2 Ancillary Study) 14–16 involving 26 US 
centers that prospectively recruited CP patients 2000–2014. CP was defined as definitive 
evidence of CP on either (1) endoscopic retrograde cholangiopancreatography using the 
Cambridge classification or magnetic resonance cholangiopancreatography (MRCP), (2) 
computed tomography (CT) scan, or endoscopic ultrasound (EUS) (≥5 criteria or 
calcifications), or 3) histologic evidence of CP 14. Data in this study was also collected by 
sets of questionnaires completed by the patient and the physician. Some adult patients 
included in this study have been previously reported 14–16.
Questionnaires for INSPPIRE were modeled after those for NAPS2, adapted for children. 
Both studies collected similar information on demographics, family and personal history, 
environmental history including smoking and alcohol consumption, and clinical questions 
related to pancreatitis, medication use, and disability. The similarity in study methodology 
allows comparison of these two cohorts. Physician questionnaires included documentation 
of risk factors and medical or surgical therapies prior to enrollment 14, 18. Risk factors for 
CP were by physician report, using the physicians’ determination for the significance of 
alcohol or tobacco use, hypertriglyceridemia and hypercalcemia. Duration of disease was 
calculated from the time of first diagnosis of acute pancreatitis (AP), CP, or symptoms of 
pancreatitis (whichever came first) to entry into either NAPS2 or INSPPIRE.
In INSPPIRE, genetic risk factors were extracted from the physician report; the number of 
CP risk factor genes tested was variable. For the NAPS2 cohort, results reported here are 
based on post hoc testing for mutations in four genes (PRSS1 (cationic trypsinogen gene), 
CFTR (cystic fibrosis transmembrane conductance regulator gene), SPINK1 (serine protease 
inhibitor Kazal type 1 gene), CTRC (chymotrypsin C gene)) that all subjects underwent as 
part of a research study 25. Analysis was done in a single laboratory by a combination of 
sequencing and Taq-man® assays (Thermo-Fischer, Waltham MA).
Statistical analysis
Demographic, clinical, and treatment variables were compared between pediatric and adult 
patients using t-test or Wilcoxon rank-sum test for continuous variables, Pearson chi-square 
test or Fisher’s exact test for categorical variables, and Wilcoxon rank-sum test for ordinal 
variables. Summary statistics are presented as mean (standard deviation) or median 
(interquartile range, IQR) for continuous variables, frequency count (percent) or median 
(IQR) for ordinal variables, and frequency count (percent) for categorical variables. All 
statistical analyses were performed using SAS (version 9.4).
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Results
Population
The NAPS2 cohort included 1,195 subjects. Of these, 1,063 had age at onset of symptoms or 
diagnosis of AP or CP (whichever came first) as adults (>18 years); 76 reported onset of 
symptoms or diagnosis of AP or CP at <18 years of age; age at onset of symptoms could not 
be determined in the remaining 56 patients. The INSPPIRE cohort included 224 childhood-
onset CP subjects. None were in the NAPS2 cohort. All subjects included in the study met 
criteria for CP at enrollment in the study.
In the primary analysis, the 1,063 NAPS2 subjects with adult onset of disease were 
compared with the 224 INSPPIRE subjects with childhood onset. As a secondary analysis, 
the NAPS2 subjects with childhood onset were compared with the INSPPIRE subjects. In 
the secondary analysis, only the subjects specifying white race were compared (158 
INSPPIRE, 69 NAPS2) because of the small size of the non-white population (n=7) in this 
NAPS2 subset.
Demographics
Demographic data for the primary analysis from the two cohorts are presented in Table 1. 
Age at presentation of CP was, by definition, divergent. Children presented at a mean age of 
11.9±3.9 years, while adults presented at a mean age of 52.7±13.3 years. The cohorts were 
similar with respect to race. Female sex was more common in the pediatric cohort (56% 
female in pediatric cohort vs 45% in adult cohort, p=0.003). Adults with CP were more 
likely to be overweight or underweight, compared with children (adult cohort 10% 
underweight and 27% overweight vs pediatric cohort 5% underweight and 13% overweight, 
p=0.001 and p<0.0001, respectively). History of acute or acute recurrent pancreatitis was 
reported in pediatric CP 92% and 83%, respectively versus 71% and 66% of adult CP 
(p<0.0001 for each). Family history of CP was significantly more common in children with 
CP (23% in children vs 8% in adults, p<0.0001). This may reflect the difference in risk 
factors for the two groups, discussed below.
The pediatric cohort had a mean period of 3.6±3.3 years from patient or physician-reported 
presentation of disease to enrollment in INSPPIRE while adults had a 6.9±7.1 year period 
between disease onset and enrollment (p<0.0001).
Risk factors
Risk factors for CP in the two populations are presented in Table 2. Adults reported 
environmental risk factors significantly more than children. Alcohol exposure was a risk in 
53% of adults and 1% of children (p<0.0001), and tobacco exposure was a risk in 50% of 
adults and 7% of children (p<0.0001). Hypertriglyceridemia was also more common in 
adults (11%) vs. children (4%) (p=0.007). Medications were more frequently identified as 
risk factors in children compared with adults (7% vs 3%, p=0.0007). Children were more 
likely to be diagnosed with autoimmune pancreatitis than adults (6% vs 2%, p=0.039). 
Obstructive factors were found more commonly in children (29%) compared with adults 
(19%), p=0.001).
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Analysis of four genetic risk factors for CP, PRSS1, SPINK1, CFTR and CTRC, was done in 
every adult. As children were tested as part of clinical care, and often for a more limited 
group of genes, all four genetic risk factor results are not available for all children. Despite 
the more complete testing in adults, all four genetic risk factors were significantly more 
common in children than adults (p<0.0001 for each gene, Table 2).
Morphologic features
Morphologic features of the pancreas and biliary tree are important in the diagnosis of CP. 
Few differences were found between imaging features of the pancreas and biliary tree in 
adults and children (Table 3). Pancreatic calcifications, cysts and pseudocysts were 
significantly more common in adults (calcifications, 15% in children vs 57% in adults, p 
<0.0001; cysts/pseudocysts 22% in children vs 31% in adults, p =0.007). Pancreatic atrophy 
(fatty or fibrous replacement of the pancreas), which has been reported as more common in 
children with CP 2 was equal in occurrence in children and adults in this head-on 
comparison (p = 0.063).
Disease impact
The impact of CP was measured as frequency and intensity of pain, frequency of 
complications (exocrine pancreatic insufficiency or diabetes), and frequency of interference 
with daily life (Table 3). Pain was common in both adults and children, in both groups only 
13–14% reported being always or usually pain-free. Adults reported more pain overall, with 
a higher percentage of adults reporting constant mild-moderate pain with episodes of severe 
pain. However, prevalence of constant severe pain was similar between the two groups (5% 
of children, 6% of adults). Adults were more likely to use pain medication of any kind (57% 
of children vs 70% of adults, p=0.0006), and more commonly used opioids either alone or in 
combination with non-opioids (children 42% vs adults 62%, p<0.0001).
Prevalence of exocrine pancreatic insufficiency was similar between the adult and pediatric 
cohorts (children 26% vs adult 33%, p=0.107). Diabetes was more commonly reported in 
adults than in children (36% vs 4% respectively, p<0.0001). Median number of emergency 
room visits and hospitalizations, as well as missed days of work and school in the year 
preceding enrollment were similar across both cohorts.
Medical and surgical treatment
Suppl Table 1 includes therapies used for CP in the children and adults. Adults were more 
likely to use pancreatic enzymes (children 55% vs adults 66%, p=0.004). Children were 
more likely to have undergone pancreatic duct sphincterotomy (p<0.0001) and pancreatic 
duct stone removal (p<0.0001) compared with adults and less likely to have undergone 
cholecystectomy (p=0.0002).
Secondary population analysis
Table 4 compares demographic and risk factors of 69 white adults from NAPS2 who 
reported their CP began in childhood and 158 white subjects from the INSPPIRE cohort. 
These two cohorts were much more similar than the entire INSPPIRE and NAPS2 cohorts. 
Percent female sex was similar in these two groups, with the INSPPIRE cohort 51% female 
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and the NAPS2 childhood onset cohort at 54% female. Prevalence of family history of CP 
and presence of genetic risk factors were similar between the two groups, as was the 
presence of pancreas divisum. The only risk factor significantly more common in the 
NAPS2 childhood onset cohort compared to the INSPPIRE cohort was alcohol as a risk 
factor (9% in NAPS2 and 1% in INSPPIRE cohorts, p=0.011). Disease duration for the two 
cohorts was different; however, comparison was not made as the difference may be due to 
the study start periods.
Discussion
The NAPS2 and INSPPIRE cohorts allow large studies of demographics, risk factors, 
clinical course and therapies in adults and children, respectively, with CP. Our comparison of 
these two large databases shows that children have few differences and many similarities in 
demographics, complications and therapies. In contrast, marked differences exist in risk 
factors between children and adults.
In studies of children with CP, the most common physician-reported risk factors are genetic 
variants associated with CP 2, 10–12, 17, 26. Adults more commonly have environmental risk 
factors, particularly alcohol and smoking 3, 8, 27, 28. Even when adults with CP were tested 
post hoc, the presence of known genetic risk factors was significantly lower than in children. 
This difference may account for the difference in age of presentation of disease. It is likely 
that genetic risk factors with significant penetrance lead to onset of CP in childhood, 
whereas the older age when alcohol and tobacco use begins and the length of use contributes 
to adult-onset CP. The finding that adults with CP in the NAPS2 study who presented during 
childhood have a similar frequency of genetic risk factors compared with the INSPPIRE 
cohort supports this hypothesis. It is also possible that adults with CP have less penetrant 
genetic risk factors and thus manifest later in life or when an environmental risk factor is 
introduced. It should be noted that the degree to which second-hand smoke might contribute 
to childhood CP is undetermined, as unbiased analysis of the risk of second-hand smoke (for 
example, using urine or blood cotinine levels) has not been done.
When comparing the INSPPIRE cohort with the patients in NAPS2 who presented as 
children, we did not find significant differences in the prevalence of genetic variants between 
the groups. Although a previous report found that PRSS1 and CTRC mutations are more 
prevalent in early childhood CP 22, only PRSS1 approached significance (p = 0.059) in our 
analysis. The average age of initial presentation of CP is older in the adults in NAPS2 who 
presented as children compared to the INSPPIRE cohort. This may explain the difference in 
the prevalence of PRSS1 and CTRC mutations.
Of great clinical significance, our data shows that children and adults report similar pain 
patterns in terms of severity and frequency of daily pain. Pain is one of the most severe 
complications of CP, and the factor most likely to lead to disability. Pain intensity is a 
subjective measure; thus, it is striking that both groups describe their pain patterns so 
similarly. Despite comparable reports of pain frequency and intensity, children report less 
pain medication use than adults. Our study cannot determine what level of pain management 
is appropriate, but these data suggest that investigation of the adequacy of pain management 
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in adults and children is crucial to limit the long-term effects of too little or too much pain 
control. Increased use of pain scales and protocol medication management may improve 
control and outcome for both adults and children.
Overall children and adults have a similar incidence of complications with a few exceptions. 
Adults have more pancreatic calcifications on imaging and are more likely to develop 
diabetes. American adults in general have a high background risk of diabetes (12.2% in 
people in America > 18 years of age 29), but adults with CP have >2 times the baseline risk. 
The differences in pancreatic calcifications and diabetes between adults and children may, in 
part, result from the differing risk factors associated with CP, or possibly disease duration, 
rather than the age of the patient at disease onset 30. In the group of adult subjects with 
disease onset in childhood there was also a higher frequency of pancreatic calcification and 
diabetes in adulthood compared to the pediatric population (data not shown). This suggests 
that endocrine (but not exocrine) insufficiency is dependent on longer disease duration, as 
both groups have similar risk factors for CP. The NAPS2 childhood onset cohort was close 
to the same age as the INSPPIRE cohort at their first episode of pancreatitis, but older at the 
age of diagnosis of pancreatitis. It is possible that environmental factors, such as alcohol or 
tobacco become risks as children with a previous episode of pancreatitis age into their teens.
In our cohorts, the most common risk factors in adults were alcohol and tobacco use; in 
children genetic and obstructive risk factors were more common. Alcoholic pancreatitis has 
a more rapid progression than genetic or idiopathic pancreatitis 31–33, and cigarette smoking 
has a high prevalence of pancreatic calcifications and increases risk for exocrine pancreatic 
insufficiency 34, 35. Additionally, cigarette smoking often correlates with alcohol use 36. 
Both alcohol use and tobacco use are independently associated with development of insulin 
resistance 37, 38. Thus, in children and adults with similar length of CP, adults with CP 
would be more likely to exhibit advanced radiographic disease and be more likely to have 
diabetes. In this respect, children are more similar to adult women with CP, whose 
pancreatic morphology is different from men, likely reflecting different risk factors 
associated with their CP 27.
Our study has limitations. Both the NAPS2 and the INSPPIRE recruited subjects from 
secondary and tertiary treatment centers; individuals with milder forms of CP may not 
present at these centers and be underrepresented. The NAPS2 study is limited to the USA 
while the INSPPIRE cohort includes subjects from sites outside the USA Environmental risk 
factors or clinical management may differ between countries. The discrepancy in size of 
cohorts may also affect statistical analysis.
In conclusion, despite the disparity in age of onset of disease, children and adults with CP 
exhibit remarkable similarity in demographics, treatment of CP, and experience of pain. 
Differences between the groups with respect to radiographic findings and prevalence of 
diabetes may be related to the differences found in the risk factors associated with disease 
and the length of time they have had CP. Typically, children and adults with CP are 
diagnosed and managed by separate medical teams. Our study suggests that to understand 
the natural history of CP we need to include both children and adults in future studies.
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What is known
• Chronic pancreatitis (CP) is a devastating disease leading to pain and lost 
school/work time.
• Understanding the similarities and differences in CP between these groups is 
critical to providing appropriate care to children in transition from pediatric to 
adult providers.
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What is new
• Children and adults with CP exhibit remarkable similarity in demographics, 
treatment of CP, and pain experience.
• Adults and children with CP have different risk factors for their disease: 
genetic factors in children versus alcohol and smoking in adults. This may 
explain the variations in disease progression in these two populations.
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Table 1.
Demographic characteristics of pediatric and adult subjects with chronic pancreatitis in the INSPPIRE and 
NAPS2 cohorts
All CP
Pediatric (n=224) Adult (n=1063) Odds Ratio (95% CI) Pediatric/Adult p-value
Age at enrollment (n=214) (n=1063)
 Mean±SD 11.9±3.9 52.5±13.3
 Median (IQR) 12.6 (9.7–15.2) 52.7 (43.2–61.5)
Age at first diagnosis AP (n=157) (n=633)
 Mean±SD 8.1±4.3 43.0±14.0
 Median (IQR) 7.7 (4.5–11.6) 43.0 (32.0–52.0)
Age at diagnosis CP (n=172) (n=1035)
 Mean±SD 9.8±4.1 49.1±13.4
 Median (IQR) 9.9 (6.7–12.8) 49.0 (39.0–58.0)
Sex (Female) 125/223 (56%) 479 (45%) 1.56 (1.16, 2.08) 0.003
Race (White) 158/192 (82%) 813/1062 (77%) 1.42 (0.96, 2.12) 0.080
BMI* (n=216) (n=1050)
 Underweight 10 (5%) 102 (10%) 0.33 (0.17, 0.65) 0.001
 Normal 146 (68%) 496 (47%) (ref)#
 Overweight 29 (13%) 289 (27%) 0.34 (0.22, 0.52) <0.0001
 Obese 31 (14%) 163 (16%) 0.65 (0.42, 0.99) 0.046
History of acute pancreatitis 180/196 (92%) 662/930 (71%)*** 4.55 (2.68, 7.74) <0.0001
History of ARP 161/195 (83%) 457/690 (66%) 2.41 (1.61, 3.61) <0.0001
Family history of CP** 42/185 (23%) 81 (8%) 3.56 (2.36, 5.38) <0.0001
Family history of AP 52/177 (29%) 71 (7%) 5.81 (3.88, 8.70) <0.0001
Disease duration (n=170)
 Mean±SD 3.6±3.3 6.9±7.1
 Median (IQR) 2.7 (0.9–5.4) 4.3 (2.0–9.4) <0.0001
N, number of patients, is noted for an individual variable if fewer patients or physicians completed the appropriate question in the questionnaires. 
Where no “n” is noted for a variable the “n” is the whole cohort.
AP: Acute Pancreatitis; ARP: acute recurrent pancreatitis; CP: Chronic Pancreatitis
*
BMI categories for pediatric patients based on percentile rankings using CDC data; underweight is <5th percentile, normal is 5th–85th percentile, 
overweight is ≥85th percentile, obese is ≥95th percentile, for age and gender. BMI categories for adults: underweight <18; normal 18-<25; 
overweight 25-≤30; obese >30.
**
Family history of CP is for first degree relatives.
***
In 133 adult patients, the enrolling physician indicated a history of acute pancreatitis to be unclear or unknown, or the information was missing.
#Normal weight was the reference category
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Table 2.
Distribution of risk factors in pediatric and adult subjects with chronic pancreatitis according to the TIGAR-O 
classification in the INSPPIRE and NAPS2 cohorts
All CP
Pediatric (n=224) Adult (n=1063) Odds Ratio (95% CI) Pediatric/Adult p-value
Toxic/Metabolic Factors
Alcohol 3/220 (1%) 562 (53%) 0.01 (0.004, 0.04) <0.0001
Tobacco (Active or Passive) 15/212 (7%) 536 (50%) 0.07 (0.04, 0.13) <0.0001
Hypertryglyceridemia 7/173 (4%) 113 (11%) 0.35 (0.16, 0.77) 0.007
Hypercalcemia 0/180 (0%) 9 (1%) -- 0.373
Medications 14/188 (7%) 28 (3%) 2.97 (1.54, 5.76) 0.0007
Chronic renal failure 1/191 (1%) 19 (2%) 0.29 (0.01, 1.84) 0.343
Genetic mutations*
 PRSS1 69/156 (44%) 20/1028 (2%) 39.97 (23.21, 68.85) <0.0001
 SPINK1 32/142 (23%) 69/1005 (7%) 3.95 (2.48, 6.27) <0.0001
 CFTR 42/149 (28%) 151/1017 (15%) 2.25 (1.51, 3.35) <0.0001
 CTRC 8/96 (8%) 10/1030 (1%) 9.27 (3.08, 26.74) <0.0001
Autoimmune
Autoimmune pancreatitis 9/162 (6%) 26 (2%) 2.35 (1.08, 5.10) 0.039
Other autoimmune diseases 13/189 (7%) 29 (3%) 2.63 (1.34, 5.16) 0.004
Obstructive Factors 58/200 (29%) 200 (19%) 1.76 (1.25, 2.48) 0.001
Pancreas divisum 25/195 (13%) 91 (9%) 1.57 (0.99, 2.27) 0.059
Sphincter of oddi dysfunction 3/191 (2%) 57 (5%) 0.28 (0.09, 0.91) 0.024
Gallstones 7/195 (4%) 54 (5%) 0.70 (0.31, 1.55) 0.373
Duct obstruction 6/195 (3%) 54 (5%) 0.59 (0.25, 1.40) 0.228
n, number of patients, is noted for an individual variable if fewer patients or physicians completed the appropriate question in the questionnaires. 
Where no “n” is noted for a variable the “n” is the whole cohort.
Note that some patients had more than one risk factor.
CP: Chronic Pancreatitis
*Genetic mutations reported in children based on physician report (not all genes tested in all children); genetic mutations in adults is based on post 
hoc testing of all four genes in number noted in denominator.
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Table 3.
Select morphological features, exocrine and endocrine insufficiency, pain, resource utilization, and disability 
in pediatric and adult subjects with chronic pancreatitis in the INSPPIRE and NAPS2 cohorts
All CP
Pediatric (n=224) Adult (n=1063) Odds Ratio (95% CI) 
Pediatric/Adult
p-value
Pattern of abdominal pain* (n=203) (n=572) (significantly greater 0.030
- No abdominal pain 28 (14%) 79 (14%) pain level in adults)
- Usually pain free; episodes of mild-moderate pain 28 (14%) 73 (13%)
- Constant mild-moderate pain 12 (6%) 24 (8%)
- Usually pain free; episodes of severe pain 60 (30%) 104 (18%)
- Constant mild-moderate pain; episodes of severe pain 63 (31%) 257 (45%)
- Constant severe pain 12 (6%) 35 (6%)
Pain medications 125/219 (57%) 398/569 (70%) 0.57 (0.41, 0.79) 0.0006
 Narcotics 89/210 (42%) 353/569 (62%) 0.45 (0.33, 0.81) <0.0001
 Non-narcotics** 27/210 (13%) 45/569 (8) 1.72 (1.04, 2.85) 0.034
ER visits last year (n=186) (n=470)
 Median (IQR) 2 (0–3) 2 (0–5) 0.091
ER visits lifelong (av/yr of those dx duration>1yr) (n=98) (n=413)
 Median (IQR) 1.4 (0.4–2.8) 1.4 (0.6–3.6) 0.133
Hospitalizations last year (n=188) (n=679)
 Median (IQR) 1 (0–3) 1 (0–3) 0.667
Hospitalizations lifelong (av/yr of those dx duration >1yr) (n=98) (n=625)
 Median (IQR) 1.3 (0.5–2.8) 0.9 (0.4–2.5) 0.499
Days missed school/work last month (n=153) (n=532)
Median (IQR) 2 (0–8) 0 (0–5) 0.0006
Calcifications 25/169 (15%) 608 (57%) 0.13 (0.08, 0.20) <0.0001
Cysts/Pseudocysts 43/200 (22%) 330 (31%) 0.61 (0.42, 0.87) 0.007
Pancreatic Atrophy 71/170 (42%) 366 (34%) 1.37 (0.98, 1.90) 0.063
Exocrine insufficiency*** 48/185 (26%) 339 (33%) 0.75 (0.53, 1.07) 0.107
Endocrine insufficiency*** 8/189 (4%) 384 (36%) 0.08 (0.04, 0.16) <0.0001
n, number of patients, is noted for an individual variable if fewer patients or physicians completed the appropriate question in the questionnaires. 
Where no “n” is noted for a variable the “n” is the whole cohort.
CP: Chronic Pancreatitis
*
Data for pattern of pain in Adults is shown for NAPS2-CV/AS only
**
Pain medication use in adult patients reported by physicians was organized in a hierarchical question: patients who were taking non-narcotics 
along with narcotics are assigned into the narcotic group; Pain medication use in INSPPIRE are based on physician or patient report
***Omits subjects who had total pancreatectomy
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Table 4.
Demographic characteristics and risk factors for chronic pancreatitis in white subjects with chronic 
pancreatitis among pediatric patients (INSPPIRE cohort) and those presenting as children in the NAPS2 
cohort
Pediatric (n=158) Adult (n=69) Odds Ratio (95% CI) Pediatric/Adult p-value
Age at enrollment (n=152) (n=69)
 Mean±SD 12.1±3.8 24.7+12.0
 Median (IQR) 12.8 (10.3–15.1) 21.8 (16.3–30.6)
Age at first diagnosis AP (n=111) (n=52)
 Mean±SD 8.2±4.3 9.4+4.9
 Median (IQR) 8.1 (4.9–11.8) 9.0 (5.0–14.0)
Age at diagnosis CP (n=121) (n=61)
 Mean±SD 9.9±4.0 19.5+10.9
 Median (IQR) 10.0 (7.0–12.8) 18.0 (10.9–23.0)
Sex (Female) 81 (51%) 37/76 (54%) 1.11 (0.64, 1.92) 0.712
Family history of CP 50/141 (35%) 16 (23%) 1.82 (0.94, 3.51) 0.072
Family history of AP 41/132 (31%) 17 (25%) 1.38 (0.71, 2.67) 0.340
Disease Duration (n=123)
 Mean±SD 3.6±3.5 15.6+11.9
 Median (IQR) 2.6 (1.0–6.1) 13 (6–22)
Toxic/Metabolic Factors
Alcohol 2 (1%) 6 (9%) 0.13 (0.01, 0.79) 0.011
Tobacco (Active or Passive) 10/155 (6%) 9 (13%) 0.46 (0.18, 1.19) 0.102
Hyperlipidemia 5/126 (4%) 0 (0%) -- 0.163
Hypercalcemia 0/129 (0%) 0 (0%) -- --
Medications 10/135 (7%) 3 (4%) 1.76 (0.43, 10.26) 0.549
Chronic renal failure 1/137 (1%) 0 (0%) -- 1.00
Genetic mutations^
 PRSS1 56/118 (47%) 23 (33%) 1.81 (0.97, 3.35) 0.059
 SPINK1 22/105 (21%) 15 (22%) 0.95 (0.46, 2.00) 0.901
 CFTR 30/109 (28%) 18 (27%) 1.08 (0.54, 2.13) 0.833
 CTRC 4/73 (5%) 1 (2%) 3.94 (0.37, 196.93) 0.367
Autoimmune
Autoimmune pancreatitis 9/116 (8%) 1 (2%) 5.72 (0.76, 254.3) 0.093
Other autoimmune diseases 10/134 (7%) 2 (3%) 2.70 (0.55, 25.96) 0.228
SAP associated CP 6/86 (7%) 1 (2%) 5.10 (0.59, 238.0) 0.132
Obstructive Factors 39/143 (27%) 15 (22%) 1.35 (0.68, 2.67) 0.386
Pancreas divisum 15/141 (11%) 9 (13%) 0.79 (0.33, 1.92) 0.607
Sphincter of oddi dysfunction 2/137 (1%) 3 (4%) 0.33 (0.03, 2.93) 0.337
Gallstones 6/139 (4%) 0/43 (0%) -- 0.338
Pancreaticobiliary malunion 3/139 (2%) NA --
Traumatic PD stricture 0/138 (0%) 0 (0%) -- --
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Pediatric (n=158) Adult (n=69) Odds Ratio (95% CI) Pediatric/Adult p-value
Duct obstruction 5/141 (4%) 4 (6%) -- 0.480
Biliary cyst 2/141 (1%) NA --
n, number of patients, is noted for an individual variable if fewer patients or physicians completed the appropriate question in the questionnaires. 
Where no “n” is noted for a variable the “n” is the whole cohort.
Note that some patients had more than one risk factor.
AP: Acute Pancreatitis; CP: Chronic Pancreatitis; SAP: Severe Acute Pancreatitis; PD: Pancreatic Duct
*
Results of genetic mutations in adults is based on post hoc testing
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